Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
715 (USA) · Dr. Moreau
consented 2012-11-18
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate NEPHROLITHIASIS — outcome: RECOVERED/RESOLVED; onset 2013-01-10 (study day 54.0); relationship: NONE
Data queries
No data queries.